(NASDAQ: REGN) Regeneron Pharmaceuticals's forecast annual revenue growth rate of 7.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Regeneron Pharmaceuticals's revenue in 2024 is $13,100,100,000.On average, 9 Wall Street analysts forecast REGN's revenue for 2024 to be $1,537,964,623,083, with the lowest REGN revenue forecast at $1,455,836,976,938, and the highest REGN revenue forecast at $1,589,180,167,103. On average, 9 Wall Street analysts forecast REGN's revenue for 2025 to be $1,650,862,893,167, with the lowest REGN revenue forecast at $1,533,793,220,310, and the highest REGN revenue forecast at $1,722,158,643,254.
In 2026, REGN is forecast to generate $1,781,214,767,297 in revenue, with the lowest revenue forecast at $1,498,511,822,250 and the highest revenue forecast at $1,903,021,535,298.